Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Expenses (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Operating Expenses readings, the most recent being $594.6 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 22.42% to $594.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 billion, a 25.58% increase, with the full-year FY2025 number at $2.2 billion, up 25.58% from a year prior.
  • Operating Expenses hit $594.6 million in Q4 2025 for Neurocrine Biosciences, up from $555.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $594.6 million in Q4 2025 to a low of $205.1 million in Q1 2021.
  • Median Operating Expenses over the past 5 years was $372.0 million (2023), compared with a mean of $396.7 million.
  • Biggest five-year swings in Operating Expenses: soared 97.79% in 2021 and later decreased 22.18% in 2024.
  • Neurocrine Biosciences' Operating Expenses stood at $348.3 million in 2021, then dropped by 11.4% to $308.6 million in 2022, then grew by 18.24% to $364.9 million in 2023, then soared by 33.1% to $485.7 million in 2024, then increased by 22.42% to $594.6 million in 2025.
  • The last three reported values for Operating Expenses were $594.6 million (Q4 2025), $555.9 million (Q3 2025), and $541.9 million (Q2 2025) per Business Quant data.